CSL Limited
CSL
Pozycja w akcjach
#364
CSL Limited operates as a global biopharmaceutical company, engaged in the... CSL Limited operates as a global biopharmaceutical company, engaged in the research, development, manufacturing, marketing, and distribution of diverse pharmaceutical and allied products. Its extensive international footprint includes key markets such as Australia, the United States, Germany, the United Kingdom, Switzerland, and China. The company is structured into two principal operating segments: CSL Behring and CSL Seqirus. CSL Behring focuses on plasma-derived therapies, encompassing both plasma products and recombinant treatments. This segment also conducts significant research into both plasma and non-plasma therapeutics and derives revenue from intellectual property licensing and royalties. In contrast, CSL Seqirus is dedicated to the manufacturing and worldwide distribution of non-plasma biotherapeutic products, alongside developing a range of influenza-related solutions. Founded in 1916, CSL Limited maintains its corporate headquarters in Parkville, Australia.
Cena akcji
$138.33
Kapitalizacja rynkowa
$66.38B
Zmiana (1 dzień)
-0.22%
Zmiana (1 rok)
-3.31%
Kraj
AU
Handel CSL Limited (CSL)
Kategoria
Healthcare
Przychody dla CSL Limited (CSL)
Przychody w Jun 2026 TTM: $15.74B
Według najnowszych raportów finansowych CSL Limited, obecny przychód firmy (TTM) wynosi $15.74B. W roku 2024 firma osiągnęła przychód w wysokości $14.69B wzrost w porównaniu do przychodu z roku 2023, który wynosił $13.17B. Przychód to całkowita kwota dochodu generowana przez firmę ze sprzedaży towarów lub usług. W przeciwieństwie do zysku, nie są odliczane żadne koszty.
Historia przychodów firmy CSL Limited od 2000 do 2026
Przychody na koniec każdego roku
| Rok | Przychody | Zmień |
|---|---|---|
| 2026 (TTM) | $15.74B | 2.04% |
| 2025 | $15.43B | 5.04% |
| 2024 | $14.69B | 11.51% |
| 2023 | $13.17B | 25.55% |
| 2022 | $10.49B | 1.56% |
| 2021 | $10.33B | 9.84% |
| 2020 | $9.41B | 13.08% |
| 2019 | $8.32B | 11.54% |
| 2018 | $7.46B | 6.28% |
| 2017 | $7.02B | 15.81% |
| 2016 | $6.06B | 11.00% |
| 2015 | $5.46B | 8.91% |
| 2014 | $5.01B | 10.79% |
| 2013 | $4.52B | -2.44% |
| 2012 | $4.64B | -3.37% |
| 2011 | $4.80B | 49.63% |
| 2010 | $3.21B | 6.25% |
| 2009 | $3.02B | -7.53% |
| 2008 | $3.26B | 42.87% |
| 2007 | $2.28B | 45.52% |
| 2006 | $1.57B | -1.58% |
| 2005 | $1.60B | 98.59% |
| 2004 | $803.28M | 36.45% |
| 2003 | $588.71M | 38.88% |
| 2002 | $423.90M | -2.21% |
| 2001 | $433.49M | 0.00% |
| 2000 | 0.00 | 0.00% |
Przychody podobnych firm lub konkurentów
| Firma | Przychody | Różnica w przychodach | Kraj |
|---|---|---|---|
| $12.62B | -19.82% |
US
|
|
| $2.23B | -85.85% |
US
|
|
| - | - |
CH
|
|
| $6.02B | -61.76% |
NL
|
|
| $10.11B | -35.78% |
BE
|
